EMA safety committee finds no causal link between GLP-1 drugs and suicidal thoughts

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) concluded that the available evidence does not support a causal association between GLP-1 receptor agonists (dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide) and suicidal or self-injurious thoughts and actions. The review weighed non-clinical studies, clinical trials, post-marketing reports and two large electronic health record studies. No update to EU product information was required.